Effect of physio-chemical seed treatments on opium poppy downy mildews caused by Peronospora meconopsidis and P. somniferi

por Thangavel, Tamilarasan, Scott, Jason, Jones, Suzanne, Gugalothu, Ramya, Wilson, Calum
Publicado 2020

“The students keep me hopeful”: Teacher hope during the COVID-19 pandemic

por Jones, Suzanne H., Putney, LeAnn G., Campbell, Brett D., Longhurst, Max
Publicado 2023

The impact of the introduction of liquid based cytology on the variation in the proportion of inadequate samples between GP practices

por Harrison, Wayne N, Teale, Alison MJ, Jones, Suzanne P, Mohammed, Mohammed A
Publicado 2007

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

por Sager, Philip T, Balser, Barbara, Wolfson, Julie, Nichols, Jean, Pilot, Richard, Jones, Suzanne, Burris, Howard A
Publicado 2015

 A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

por Johnson, Melissa L, Patel, Manish R, Aljumaily, Raid, Jones, Suzanne F, Burris, III, Howard A, Spigel, David R
Publicado 2023

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

por Laille, Eric, Patel, Manish, Jones, Suzanne F., Burris, Howard A., Infante, Jeffrey, Lemech, Charlotte, Liu, Liangang, Arkenau, Hendrik‐Tobias
Publicado 2015

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

por Brown, Jacqueline, Scardo, Savannah, Method, Michael, Schlauch, Dan, Misch, Amanda, Picard, Shaita, Hamilton, Erika, Jones, Suzanne, Burris, Howard, Spigel, David
Publicado 2022

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

por Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Publicado 2023

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

por Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Publicado 2013

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor...

por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado 2017

Can wearable technology be used to approximate cardiopulmonary exercise testing metrics?

por Jones, Laura, Tan, Laura, Carey-Jones, Suzanne, Riddell, Nathan, Davies, Richard, Brownsdon, Ashleigh, Kelson, Mark, Williams-Thomas, Rhys, Busse, Monica, Davies, Michael M., Morgan, Matt P. G.
Publicado 2021

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings

por Sturgill, Emma G, Misch, Amanda, Jones, Carissa C, Luckett, Daniel, Fu, Xiaotong, Schlauch, Dan, Jones, Suzanne F, Burris, Howard A, Spigel, David R, McKenzie, Andrew J
Publicado 2022

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado 2015

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

por Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Publicado 2013

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

por Johnson, Melissa L., Wang, Judy S., Falchook, Gerald, Greenlees, Carol, Jones, Suzanne, Strickland, Donald, Fabbri, Giulia, Kennedy, Caroline, Elizabeth Pease, J., Sainsbury, Liz, MacDonald, Alexander, Schalkwijk, Stein, Szekeres, Philip, Cosaert, Jan, Burris, Howard
Publicado 2023

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

por Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, Howard A, Zamboni, William C
Publicado 2015

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

por Bauer, Todd M., Moore, Kathleen N., Rader, Janet S., Simpkins, Fiona, Mita, Alain C., Beck, J. Thaddeus, Hart, Lowell, Chu, Quincy, Oza, Amit, Tinker, Anna V., Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David, Fu, Siqing
Publicado 2023

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanc...

por Bendell, Johanna C., Kelley, Robin K., Shih, Kent C., Grabowsky, Jennifer A., Bergsland, Emily, Jones, Suzanne, Martin, Thomas, Infante, Jeffrey R., Mischel, Paul S., Matsutani, Tomoo, Xu, Shuichan, Wong, Lilly, Liu, Yong, Wu, Xiaoling, Mortensen, Deborah S., Chopra, Rajesh, Hege, Kristen, Munster, Pamela N.
Publicado 2015

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

por Wallin, Jeffrey J., Bendell, Johanna C., Funke, Roel, Sznol, Mario, Korski, Konstanty, Jones, Suzanne, Hernandez, Genevive, Mier, James, He, Xian, Hodi, F. Stephen, Denker, Mitchell, Leveque, Vincent, Cañamero, Marta, Babitski, Galina, Koeppen, Hartmut, Ziai, James, Sharma, Neeraj, Gaire, Fabien, Chen, Daniel S., Waterkamp, Daniel, Hegde, Priti S., McDermott, David F.
Publicado 2016

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

por Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, Patnaik, Amita
Publicado 2017